Sunil Gulati

opinion seeker & analyzer

[Sunil Gulati @gulatisunil]

CHI Memorial First In Region To Enroll Patient In Groundbreaking Stroke Clinical Trial https://t.co/nWHyYksdKr

[Sunil Gulati @gulatisunil]

https://t.co/wrcWDZE2Pv

[Sunil Gulati @gulatisunil]

@Pharmazz https://t.co/wrcWDZE2Pv

[Sunil Gulati @gulatisunil]

@LotusBharat @Suhelseth @narendramodi It should be both, Bharat Ratna to him and an award in his name should be constituted

[Sunil Gulati @gulatisunil]

@smitaprakash Jai Shri Ram!

[Sunil Gulati @gulatisunil]

#HappyBirthdayModiJi the words cannot express my gratitude to you for the progress the country has made under your leadership. Happy birthday Modiji.

[Sunil Gulati @gulatisunil]

https://t.co/NX2e4dKfQT

[Sunil Gulati @gulatisunil]

https://t.co/NX2e4dKfQT

[Anil Gulati, MD, PhD @ProfessorGulati]

104th patient enrolled in an ongoing prospective, multi-centric, open-labeled study of 400 patients to assess the safety and efficacy of Centhaquine (Lyfaquin®) as a resuscitative agent for shock due to severe blood or fluid loss.
@PharmICU #ICU #intensivecare #criticalcare #emergencymedicine #resuscitation #anesthesia #intensivist

[Anil Gulati, MD, PhD @ProfessorGulati]

Pharmazz, Inc. Announces Marketing Approval of Sovateltide in India for Acute Cerebral Ischemic Stroke Patients https://t.co/R1JyF9N4At

[Anil Gulati, MD, PhD @ProfessorGulati]

Tips to optimize vasopressors use in the
critically ill patient
This is an excellent summary article:
https://t.co/uL1cto8xW0
How and where Centhaquine will fit is our task to explore.
@SCCM
@SOCCA_CritCare
@ESICM
@ARC_resus
@ERC_resus
@ResusCouncilUK

[Anil Gulati, MD, PhD @ProfessorGulati]

Presentations Highlighting Centhaquine, a resuscitative agent, at The ISICEM 2023 Brussels
https://t.co/owDm6vYU15
Centhaquine is a new resuscitative medicine used to treat hemorrhagic shock, a hypovolemic shock that is often fatal.

[Anil Gulati, MD, PhD @ProfessorGulati]

a2receptor agonists appear attractive to predominantly target venous constriction to treat shock. New agent Centhaquine shows promise.

[Anil Gulati, MD, PhD @ProfessorGulati]

Meeting with Jean-Louis Vincent at the ISICEM meeting at Brussels

[Anil Gulati, MD, PhD @ProfessorGulati]

Pharmazz Team attending the ISICEM meeting at Brussels

[Anil Gulati, MD, PhD @ProfessorGulati]

Pharmazz Inc. Announces Key Publications Regarding the Role of Adrenergic Receptors in Venous Blood Return to Treat Shock https://t.co/5GG1cinJCW

[Anil Gulati, MD, PhD @ProfessorGulati]

We will share positive data from the Ph. III sovateltide study, a potential treatment for cerebral ischemic stroke.
#IPSON2023 #stroke #criticalcare #pharmazz #sovateltide

[Anil Gulati, MD, PhD @ProfessorGulati]

US FDA Clears Phase III Clinical Trial of Sovateltide (PMZ-1620) in Acute Cerebral Ischemic Stroke Patients. The primary endpoint is the proportion of patients with a mRS of 0-2 on day 90 post-randomization in 444 patients. https://t.co/kE6iEV7uzc

[Anil Gulati, MD, PhD @ProfessorGulati]

Clinical phase III trial results demonstrate sovateltide produced statistically significant and clinically meaningful improvements in neurological outcomes in acute cerebral ischemic stroke patients. Presented at ISC2023 Dallas. https://t.co/1ifUj1cGPf

[Anil Gulati, MD, PhD @ProfessorGulati]

The blood pressure is considered an essential parameter for cardiovascular function. We have described the control systems of blood pressure and their regulation in hemorrhagic/hypovolemic shock using centhaquine (Lyfaquin®) as a resuscitative agent.
https://t.co/IhOwIo8qzA